Dr. Leonard Petrucelli Earns Prestigious Sheila Essey Award for ALS Research
Founding director of the University of Miami’s Miller School’s Neuroscience Institute recognized for transformative discoveries advancing understanding, diagnosis and treatment of ALS.
Leonard Petrucelli, Ph.D., founding director of the University of Miami Miller School of Medicine’s Neuroscience Institute, has been named a recipient of the Sheila Essey Award for ALS Research. The award recognizes scientists whose work has fundamentally advanced the understanding of amyotrophic lateral sclerosis (ALS) and accelerated progress toward effective treatments.
Dr. Petrucelli received the award at this year’s American Academy of Neurology meeting.
For Dr. Petrucelli, a professor in the Miller School’s Department of Neurology whose career has been defined by landmark discoveries in neurodegenerative disease, the recognition carries both professional and personal significance.
“Receiving the Sheila Essey Award is a tremendous honor, and it is especially meaningful to me as the first award of my career,” he said. “Professionally, it is both humbling and energizing. Awards like this are a reminder that this work is far bigger than any one individual and reflects the dedication of trainees, collaborators, clinicians, patients and families who have all contributed in important ways.”
A Career Shaped by Transformative Discoveries
Dr. Petrucelli is internationally recognized for pioneering research that reshaped how scientists understand ALS and related neurodegenerative diseases. His work has focused on uncovering the molecular mechanisms that drive disease, translating those insights into tools that may eventually improve diagnosis and treatment.
Although his interest in neurodegeneration had been long‑standing, Dr. Petrucelli points to 2006 as a defining moment in his scientific trajectory, when abnormal pathology involving the protein TDP‑43 was first identified in ALS.
“When TDP‑43 pathology was first identified in ALS, it was immediately clear that this discovery would fundamentally change how we think about the disease,” he said. “I recognized that it opened an entirely new window into ALS biology and created important opportunities to better understand disease mechanisms and develop new therapeutic strategies.”
Over the years, his laboratory’s work has spanned multiple experimental systems, from animal models to patient‑derived cells. Dr. Petrucelli’s team identified abnormal proteins associated with C9orf72‑linked ALS and developed the first preclincal model of this genetic form of the disease. Their work provided the field with a critical platform for studying disease progression and testing potential interventions.
More recently, his research has continued to deepen understanding of TDP‑43, a protein disrupted in the vast majority of ALS cases and now recognized as central to disease pathogenesis.
Making ALS More Livable, Now and in the Future
While long‑term efforts are aimed at effective therapies and, ultimately, a cure, Dr. Petrucelli emphasizes that his research is equally focused on improving quality of life for people living with ALS today.
“Our work is focused on understanding ALS at its roots and using that knowledge to improve the lives of patients,” he said.
A major emphasis of his laboratory is the development of biomarkers, measurable signals in blood or other body fluids that could help diagnose ALS earlier, track disease progression more accurately and assess whether treatments are working.
“These kinds of tools are essential,” Dr. Petrucelli said. “They can improve clinical care today while also making clinical trials more efficient and informative.”
Dr. Petrucelli credits the collaborative culture of the ALS research community for sustaining his commitment to the field.
“The strength, generosity and determination of the ALS community have had a profound impact on me and continue to inspire my work every day,” he said.
About the Sheila Essey Award
Named in memory of Sheila Essey, a passionate advocate for ALS research, the award is presented annually to scientists whose work has produced transformational advances in understanding or treating the disease. Recipients are selected based on the originality, impact and translational potential of their research, as well as their commitment to collaboration and scientific leadership.
The award includes a monetary prize, which Dr. Petrucelli plans to reinvest directly into the ALS research ecosystem at the Miller School.
“I plan to use these funds to establish an annual ALS symposium at the Neuroscience Institute,” he said. “My hope is to create a forum that brings together leading scientists, clinicians and industry partners to share discoveries, exchange ideas and build the kinds of collaborations that can move the field forward more quickly.”
Looking Ahead With Realism and Hope
Despite the challenges that remain, Dr. Petrucelli is optimistic about the direction of the field.
“ALS remains an extraordinarily difficult disease and progress is never as fast as any of us would like,” he said. “But over the past decade, the field has advanced in very important ways.”
With deeper biological insight, more powerful research tools and unprecedented global collaboration, he believes meaningful breakthroughs are increasingly within reach.
“I truly believe the field is moving in the right direction,” Dr. Petrucelli said. “I am hopeful that the work being done today will lead to meaningful breakthroughs for patients and families in the years ahead.”
More from the Miller School of Medicine
Dr. Leonard Petrucelli leads two major grants advancing collaborative Parkinson’s disease research at the Miller School.
The Qalsody Clinic is one of six specialty clinics at the ALS Center tailored to meet the needs of patients with Lou Gehrig’s disease.
The internationally renowned neuroscientist brings global leadership in Alzheimer’s, ALS and frontotemporal dementia research.
The University of Miami Miller School of Medicine’s Dr. Hassan Al Ali is using advanced mathematics and algorithms to refine drug discovery work.
Tags: Aging Research, ALS, Alzheimer's disease, amyotrophic lateral sclerosis, cognitive decline, Department of Neurology, Dr. Leonard Petrucelli, Frontotemporal dementia, neurology, neuroscience, Neuroscience Institute, Newsroom